NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-GM-17-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide regional access for cryoelectron microscopy (cryoEM) laboratories to state-of-the-art data collection capabilities. NIGMS will support consortia of established and early stage investigator laboratories whose research has an established specialization in and dependence on cryoEM. These laboratories will coordinate with each other to share facilities and resources for collection of high resolution data. Consortia will consist of a host institution and partner institutions. The host institution should already have a modern high-performing cryoEM installation and proven capabilities for high-resolution data collection. A consortium will support surplus capacity for cryoEM data collection (infrastructure and services) at the host institution and make it available to participating cryoEM partner laboratories at the partner institutions. These projects will support access for these partner laboratories to resources and services at host institutions. Projects will (a) contribute to the fixed costs of maintaining the host facility and extend services in proportion to the resources dedicated to the partner laboratories and (b) support expenses of access to the facility by these partners. The host institution need not already have an electron detector; this FOA can help fund acquisition of direct detection equipment. Support is limited to enabling the cryoEM partner laboratories to collect data and perform the initial stages of processing raw images, and does not include other research activities. In addition to the host institution, consortia will include a minimum of four partner institutions; award budgets will depend on the number and data collection needs of the partner laboratories. This initiative is not intended to support service centers of the traditional type in which the host laboratory performs the cryoEM analysis for non-specialist collaborators.
Funding Opportunity PAR-17-170 from the NIH Guide for Grants and Contracts. This funding opportunity announcement encourages non-hypothesis-driven grant applications to support investigator-initiated research projects that will maintain and expand the availability of resources to serve biomedical research within NIAAAs priority areas as described in the strategic plan.
Notice NOT-FD-17-005 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-169 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to pediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy.
Notice NOT-HG-17-003 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-18-200 from the NIH Guide for Grants and Contracts. The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan and the Research Domain Criteria (RDoC) project.
Funding Opportunity PAR-17-168 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The institute seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions in basic neuroscience research, or in translational research with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research demonstrating an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms. The Conte Centers program also provides an opportunity to establish interdisciplinary basic neuroscience or translational research experiences for students and post doctorates.
Notice NOT-OD-17-043 from the NIH Guide for Grants and Contracts
Notice NOT-FD-17-002 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-013 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-032 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-17-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate multidisciplinary research projects from the scientific community that use a combination of animal/cell models and non-invasive human placenta tissues or biomarkers to investigate how early life exposures affect placental growth, development, and function, and the subsequent health of the offspring.
Notice NOT-AR-17-016 from the NIH Guide for Grants and Contracts
Notice NOT-HS-17-007 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-TR-17-001 from the NIH Guide for Grants and Contracts. The NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules [New Therapeutic Uses (NTU)] program is designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development. This innovative program matches researchers with a selection of pharmaceutical industry assets to test ideas for new therapeutic uses with the ultimate goal of identifying promising new treatments for patients. The program was designed to enable efficient 3-way drug repositioning partnerships between academic, government, and pharmaceutical partners.
Funding Opportunity RFA-TR-17-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases unique to pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition. An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-003. X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA. The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities. If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.
Funding Opportunity RFA-TR-17-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target should have a positive impact on the disease/condition. An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-003. X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA. The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities. If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.
Notice NOT-HL-17-487 from the NIH Guide for Grants and Contracts
Notice NOT-HD-17-003 from the NIH Guide for Grants and Contracts